Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02120
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Criteria:
Please see https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for full code and algorithm definitions.
Inclusion Criteria:
- Confirmed acute symptomatic proximal DVT without symptomatic PE
Exclusion Criteria:
- Age ≤ 18
- Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT or PE two weeks prior to and including day of enrollment
- Other indications for VKA than DVT and/or PE six months prior to and including day of enrollment
Any of the following six months prior to and including day of enrollment:
- Creatine clearance < 30 ml/min
- Significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or ALAT>3 ULN
- Bacterial endocarditis
- Active bleeding or high risk for bleeding contraindicating treatment with enoxaparin or VKA
- Systolic blood pressure > 180 mgHg or diastolic blood pressure > 110 mgHg
- Childbearing potential without proper contraceptive measures, pregnancy, or breastfeeding
- Life expectancy < 3 months in the last year prior to and including day of enrollment
- Concomitant use of strong CYP3A4 inhibitors (e.g. HIV protease inhibitors, systemic ketoconazole) or strong CYP3A4 inducers two weeks prior to and including day of enrollment
- Symptomatic pulmonary embolism two weeks prior to and including day of enrollment
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Warfarin
Reference group
|
Warfarin dispensing claim is used as the reference group
|
|
Rivaroxaban
Exposure group
|
Rivaroxaban dispensing claim is used as the exposure group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to first occurrence of venous thromboembolism
Time Frame: From 1 day after prescription fill until outcome occurrence or censoring due to end of follow-up, death, treatment discontinuation, nursing home admission, treatment augmentation, or switch to another NOAC, assessed up to 1 year.
|
The primary outcome is the time from 1 day after prescription fill of the exposure or comparator to the first occurrence of venous thromboembolism up to 1 year
|
From 1 day after prescription fill until outcome occurrence or censoring due to end of follow-up, death, treatment discontinuation, nursing home admission, treatment augmentation, or switch to another NOAC, assessed up to 1 year.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to first occurrence of major bleeding
Time Frame: From 1 day after prescription fill until outcome occurrence or censoring due to end of follow-up, death, treatment discontinuation, nursing home admission, treatment augmentation, or switch to another NOAC, assessed up to 1 year.
|
The control outcome is the time from 1 day after prescription fill of the exposure or comparator to the first occurrence of a major bleeding event as a control outcome up to 1 year
|
From 1 day after prescription fill until outcome occurrence or censoring due to end of follow-up, death, treatment discontinuation, nursing home admission, treatment augmentation, or switch to another NOAC, assessed up to 1 year.
|
|
Time to first occurrence of fracture or fall
Time Frame: From 1 day after prescription fill until outcome occurrence or censoring due to end of follow-up, death, treatment discontinuation, nursing home admission, treatment augmentation, or switch to another NOAC, assessed up to 1 year.
|
The control outcome is the time from 1 day after prescription fill of the exposure or comparator to the first occurrence of fracture or fall as a control outcome up to 1 year
|
From 1 day after prescription fill until outcome occurrence or censoring due to end of follow-up, death, treatment discontinuation, nursing home admission, treatment augmentation, or switch to another NOAC, assessed up to 1 year.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shirley Wang, PhD, ScM, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Embolism and Thrombosis
- Thromboembolism
- Venous Thromboembolism
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Pyrans
- Morpholines
- Oxazines
- Thiophenes
- Coumarins
- Benzopyrans
- 4-Hydroxycoumarins
- Rivaroxaban
- Warfarin
Other Study ID Numbers
Other Study ID Numbers
- 2018P002966-DUP-EINSTEIN-DVT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.